Company intelligence / Profile preview

Aclaris Therapeutics, Inc.

Wayne, Pennsylvania, United Statesaclaristx.com ↗

Ownership: Public · ACRS
Employees: ~200
Development stage: Phase 2

Overview

Aclaris is advancing multiple clinical programs including bosakitug (ATI-045) in atopic dermatitis with Phase 2b trial enrollment expected in first half of 2025, ATI-2138 with Phase 2a results expected in first half of 2025, and recently received FDA IND clearance for ATI-052 with Phase 1a/1b trial expected to begin in Q2 2025[7][8]

Therapeutic areas: ImmunologyDermatologyPulmonology
Modalities: Small moleculesmonoclonal antibodiesbispecific antibodieskinase inhibitors
Industry: Biotech

Drug pipeline

16 assets

Eskata

Approved

15 more assets in the full pipeline.

Request access →

Partnerships

Chia Tai Tianqing Pharmaceutical Group, Co., Ltd. (CTTQ)Biosion, Inc.

Financials

Market cap: $768.8M
Total revenue: $1.6M
Enterprise value: $677.3M

Beyond the preview

Go deeper on Aclaris Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aclaris Therapeutics, Inc..

Explore the full profile